Developing genetically engineered mouse models using engineered nucleases

Current status, challenges, and the way forward

Jaehoon Lee, Jae il Rho, Sushil Devkota, Young Hoon Sung, Han Woong Lee

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

The rapid development of engineered nucleases such as zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and the clustered regulated interspaced short palindromic repeats (CRISPR)/CRISPR-associated endonuclease 9 (Cas9) system has ushered in the era of ‘renaissance in precision genome engineering’ with profound potential to generate mouse models of human diseases. However, with accumulating experience, some drawbacks that we must seriously consider have appeared along with the recent advances in molecular genetics. Here, we highlight recent technical advances of engineered nucleases, discuss the challenges we have faced while using these ‘state of the art’ genome-editing technologies to generate genetically engineered mouse models (GEMs) and, and look toward the potential future uses of these technologies.

Original languageEnglish
Pages (from-to)13-20
Number of pages8
JournalDrug Discovery Today: Disease Models
Volume20
DOIs
Publication statusPublished - 2016 Feb 2

Fingerprint

Technology
Endonucleases
Zinc Fingers
Molecular Biology
Genome
Gene Editing
Transcription Activator-Like Effector Nucleases
Renaissance

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Drug Discovery

Cite this

@article{b25430af6ad34e0f8f4d1d57492321a8,
title = "Developing genetically engineered mouse models using engineered nucleases: Current status, challenges, and the way forward",
abstract = "The rapid development of engineered nucleases such as zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and the clustered regulated interspaced short palindromic repeats (CRISPR)/CRISPR-associated endonuclease 9 (Cas9) system has ushered in the era of ‘renaissance in precision genome engineering’ with profound potential to generate mouse models of human diseases. However, with accumulating experience, some drawbacks that we must seriously consider have appeared along with the recent advances in molecular genetics. Here, we highlight recent technical advances of engineered nucleases, discuss the challenges we have faced while using these ‘state of the art’ genome-editing technologies to generate genetically engineered mouse models (GEMs) and, and look toward the potential future uses of these technologies.",
author = "Jaehoon Lee and Rho, {Jae il} and Sushil Devkota and Sung, {Young Hoon} and Lee, {Han Woong}",
year = "2016",
month = "2",
day = "2",
doi = "10.1016/j.ddmod.2017.07.003",
language = "English",
volume = "20",
pages = "13--20",
journal = "Drug Discovery Today: Disease Models",
issn = "1740-6757",
publisher = "Elsevier Limited",

}

Developing genetically engineered mouse models using engineered nucleases : Current status, challenges, and the way forward. / Lee, Jaehoon; Rho, Jae il; Devkota, Sushil; Sung, Young Hoon; Lee, Han Woong.

In: Drug Discovery Today: Disease Models, Vol. 20, 02.02.2016, p. 13-20.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Developing genetically engineered mouse models using engineered nucleases

T2 - Current status, challenges, and the way forward

AU - Lee, Jaehoon

AU - Rho, Jae il

AU - Devkota, Sushil

AU - Sung, Young Hoon

AU - Lee, Han Woong

PY - 2016/2/2

Y1 - 2016/2/2

N2 - The rapid development of engineered nucleases such as zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and the clustered regulated interspaced short palindromic repeats (CRISPR)/CRISPR-associated endonuclease 9 (Cas9) system has ushered in the era of ‘renaissance in precision genome engineering’ with profound potential to generate mouse models of human diseases. However, with accumulating experience, some drawbacks that we must seriously consider have appeared along with the recent advances in molecular genetics. Here, we highlight recent technical advances of engineered nucleases, discuss the challenges we have faced while using these ‘state of the art’ genome-editing technologies to generate genetically engineered mouse models (GEMs) and, and look toward the potential future uses of these technologies.

AB - The rapid development of engineered nucleases such as zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and the clustered regulated interspaced short palindromic repeats (CRISPR)/CRISPR-associated endonuclease 9 (Cas9) system has ushered in the era of ‘renaissance in precision genome engineering’ with profound potential to generate mouse models of human diseases. However, with accumulating experience, some drawbacks that we must seriously consider have appeared along with the recent advances in molecular genetics. Here, we highlight recent technical advances of engineered nucleases, discuss the challenges we have faced while using these ‘state of the art’ genome-editing technologies to generate genetically engineered mouse models (GEMs) and, and look toward the potential future uses of these technologies.

UR - http://www.scopus.com/inward/record.url?scp=85028568575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028568575&partnerID=8YFLogxK

U2 - 10.1016/j.ddmod.2017.07.003

DO - 10.1016/j.ddmod.2017.07.003

M3 - Review article

VL - 20

SP - 13

EP - 20

JO - Drug Discovery Today: Disease Models

JF - Drug Discovery Today: Disease Models

SN - 1740-6757

ER -